ArticleBMC public health2026
Predictors of tuberculosis preventive therapy initiation among people living with HIV in the Volta region, Ghana.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a leading cause of morbidity and mortality among people living with HIV (PLHIV) despite the availability of effective preventive interventions. Tuberculosis Preventive Therapy (TPT), strongly recommended by the World Health Organization, substantially reduces the risk of active TB among PLHIV, however, uptake of TPT remains suboptimal in many settings. This study, therefore, assessed the predictors of TPT initiation, beginning the course of anti-TB medications among PLHIV.
methodsThis was a health facility-based analytical cross-sectional study among 806 PLHIV aged ≥ 18 years attending antiretroviral therapy (ART) clinics in the Volta Region of Ghana. A systematic sampling technique was employed to recruit respondents, and data were collected using structured questionnaires mounted in the Kobo Toolbox. Data was exported to Stata version 17.0 for analysis. Descriptive and logistic regression analyses were performed, with statistical significance set at a p < 0.05 at 95% confidence interval.
resultsOur study found that out of the 806 PLHIV recruited, with a mean age of 44.7 years (SD ± 13), the majority, 481 (59.70%), were found to have poor knowledge of TPT. We found that 620/806 (88.6%) PLHIV were eligible for TPT, and among those eligible, only 236 (38.1%) were initiated on TPT. Respondents who had good knowledge of TPT were about 7 times more likely to be initiated compared with those who had poor knowledge (aOR = 6.79, 95% CI 4.69-9.83, p < 0.001). Those who had been diagnosed with HIV for one year or more were 4 times as likely to be initiated as those diagnosed for less than a year (aOR = 4.18, 95% CI 1.74-10.04, p = 0.001). Respondents in HIV clinical stage 2 were 66% less likely to be initiated than those in stage 1 (aOR = 0.34, 95% CI 0.20-0.58, p < 0.001). With respect to marital status, married respondents were 40% less likely to be initiated on TPT compared with single respondents (aOR = 0.60, 95% CI 0.37-0.97, p = 0.038). Barriers perceived by PLHIV to TPT initiation were distance to facility, poor health education, and limited drug availability.
conclusionTPT initiation among PLHIV in the Volta Region was suboptimal, and key predictors of initiation were TPT knowledge, duration since HIV diagnosis, HIV clinical stage, and marital status. Strengthening patient education, ensuring consistent drug and logistics availability, and addressing implementation barriers are critical to improving uptake and advancing progress toward Sustainable Development Goal 3.3 targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.